🔴 Tvardi Therapeutics is trading 9.5% down in pre-market — no company-specific explanation identified

Tvardi Therapeutics is trading at $0.87, down -9.47%, with no company-specific announcement identified to explain the November 9 pre-market decline.

• The investor-relations page lists an October 14 conference announcement as its latest release.
• The stock rose 10.79% on November 6, but available evidence does not establish a cause for this pre-market reversal.
• Broader index futures were higher, so a same-direction market move does not explain the decline.